Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term HAART in Moderately Advanced HIV-1 (Follow-up to ACTG 315)
NCT00000891Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zidovudine, lamivudine and ritonavir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Suppression of viral replication, Delayed-type hypersensitivity (DTH) response and 1 more. Status: completed.
02
Drugs
zidovudinelamivudineritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000891.